Data from 4 randomized, placebo-controlled, double-blind trials in Indonesia, Thailand, and Vietnam, the South-East Asian Multicountry Trial on Iron and Zinc supplementation in Infants (SEAMTIZI), were pooled to investigate the effects of iron and zinc supplementation infant growth. Infants (n ¼ 2451) aged 4-6 mo old were supplemented with iron (10 mg/d) and/ or zinc (10 mg/d) for 6 mo. Overall, neither iron nor zinc supplementation prevented the progressive growth faltering during infancy, which is common in many developing countries. However, infants who received zinc were less likely to be stunted at the end of the supplementation period (odds ratio 0.80; 95% CI 0.64-1.0). Boys had a 30% higher risk of being stunted at the end of the study than girls (P , 0.01). Baseline factors modified the effect of supplementation, with infants anemic at baseline (hemoglobin , 105 g/L) benefiting from zinc supplementation, with an estimated increase in height-forage Z-score (HAZ) score of 0.17 (P , 0.01), but with no effect of zinc supplementation on growth in infants not anemic at baseline. Iron supplementation negatively affected linear growth in infants with a birth weight of .3500 g (estimated effect size, 20. 14 HAZ score; P , 0.01), but with no significant effect in infants with a lower birth weight. This study shows that blanket supplementation of infants with iron or zinc will not be beneficial to all recipients and may have adverse effects in some. Hence, interventions such as iron and zinc supplementation for infants should be restricted to subgroups in which there is a clear benefit and baseline factors should be considered and characterized before implementing new policies.
Introduction
Undernutrition and associated micronutrient deficiencies remain major health problems in many developing countries, with over one-half of the world's population affected, leading to an estimated 3.5 million deaths a year (1). Although not a specific indicator in itself, linear growth retardation in infants and children is associated with deficiencies of several micronutrients, especially of zinc (2) . Moreover, stunting and wasting are associated with significantly higher risks for morbidity and mortality (1) . A meta-analysis on the effects of micronutrient supplementation failed to show an effect of vitamin A or iron supplementation alone on linear growth, but multi-micronutrient supplementation, containing, among others, vitamin A, iron, zinc, B vitamins, and folic acid, did have a positive effect on linear growth and possibly also on ponderal growth (3) . Zinc supplementation appears to improve linear growth, especially in stunted children, and in children with initial low serum zinc concentrations (4) .
Interventions aimed at improving micronutrient status of populations or specific risk groups such as children or pregnant women are ranked among the most urgently needed and most cost-effective strategies to improve health (5) . Strategies used include supplementation (e.g. iron-folate pills for pregnant women) and fortification (e.g. fortification of fish sauce) (6) . As micronutrient deficiencies often occur concurrently, provision of a range of micronutrients simultaneously is deemed most beneficial. However, efficacy and effectiveness of this strategy might be reduced due to micronutrient interactions (7) .
Besides interactions among micronutrients that can alter the efficacy of an intervention, baseline characteristics can also have a major effect on the outcome of an intervention. In some studies, iron supplementation of iron-replete infants negatively affected growth, whereas growth was improved in iron-deficient infants (8, 9) . Moreover, in children, micronutrient supplementation has given different responses in boys and girls. For example, in the large iron and zinc supplementation trials in Nepal and Tanzania (10, 11) , male infants appear to benefit from supplementation, whereas female infants do not. Also, we showed recently that male infants have a much higher risk for iron deficiency than female infants and therefore have a larger response to iron supplementation (12) . Therefore, micronutrient effects and interactions need to be understood to predict the effectiveness of interventions.
To evaluate the effects of iron and zinc supplementation in infants in SE Asia on biochemical parameters, growth, and health, a series of parallel studies was conducted between 1996 and 2000 in a collaborative multicountry framework [SouthEast Asia Multicountry Trial on Iron and Zinc Supplementation in Infants (SEAMTIZI) 9 study group]. A core protocol for the supplementation studies was developed to be able to pool the individual data of the separate sites after completion. In this article, we report the effects of iron and/or zinc supplementation on the anthropometrical indices of the infants.
Methods
Design. The core protocol of SEAMTIZI was developed in a meeting with all principal investigators. Details of the core protocol were published previously (7) . Briefly, the protocol stipulated that infants between 4 and 6 mo of age received iron (10 mg/d as sulfate salt), zinc (10 mg/d as sulfate salt), both iron and zinc (10 mg/d each), or placebo for 6 mo. Core measurements included length, weight, and hemoglobin (Hb) and zinc concentrations. Supplements were given as a 2-mL/d dose of syrup, with all syrups also containing 15 g/L of vitamin C. Supplementation was daily, 5-7 d/wk according to site. Supplements for all sites were made by the same pharmaceutical company (PT Kenrose) in cooperation with UNICEF-Jakarta. Supplementation was double-blind and the supplements were coded with a letter at the production site. The code was revealed only after all sites had completed the trial.
Sites. For the analysis, data were pooled from 4 different research sites in Thailand [Institute of Nutrition, Mahidol University (INMU), Bangkok], Vietnam [National Institute of Nutrition (NIN), Hanoi], and Indonesia [2 sites: Trisakti University and University of Indonesia (UT/ UI), Jakarta, and the Nutrition Research and Development Centre (NRDC), Bogor (13) (14) (15) (16) ]. These research sites are described in more detail elsewhere (7) . Initially, there were 2 more research sites from Indonesia, but these were not included in the pooled data set, because 1 site had a different study design (stepped design with no iron-only group) (17) and 1 site decided not to participate in the final pooled analysis (18) .
Subjects and procedures. Ethical consent for the different study sites was obtained from the Ethical Board of Mahidol University, Bangkok, Thailand; the Ethical Committee of the Ministry of Health, Vietnam; the Ethical Committee of University of Indonesia, Jakarta, Indonesia; the Ethical Committee of Wageningen University, Wageningen, The Netherlands; and the Ethical Committee of Ministry of Health, Indonesia. Mothers of eligible infants were invited to participate in the study, informed of the procedures and purpose of the study, and informed consent was obtained. Infants were assigned to 1 of the 4 supplementation groups on the basis of individual randomization, following a computer-generated block randomized group allocation. At recruitment, infants were assessed anthropometrically and a short history concerning socioeconomic status, dietary and lactation habits, and health of the mother and infant was taken. Three of the 4 sites gave a high-dose vitamin A capsule (retinol acetate) to all infants prior to the study, with 1 site giving 150 mg (50,000 IU) (INMU) and 2 sites giving 300 mg (100,000 IU) of vitamin A (NIN and UT/UI). These sites also took baseline blood samples in all infants (NIN) or in a subsample of the infants (INMU, UT/UI). Subjects were excluded before recruitment if they had any disease requiring medical treatment or congenital abnormalities that could interfere with normal growth, and or if infants were bottle-fed.
At follow-up, infants were assessed anthropometrically, and a short history concerning health, diet, lactation, and possible adverse effects was taken. After 6 mo of supplementation, a blood sample was taken of the infant for biochemical assessment of nutritional status. All infants with a Hb concentration , 110 g/L were given iron supplementation treatment at the end of the study.
Anthropometry and biochemical analyses. Anthropometry included measurement of weight and height by trained anthropometrics using standard methods. Z-scores for weight and height [weight-for-age (WAZ), height-for-age (HAZ), and weight-for-height (WHZ)] were calculated with EPI-Info 6.02, which uses the National Centre for Health Statistics (NCHS) (1978) growth standards as well as with the new WHO (2006) Child Growth Standards for breast-fed infants (19, 20) . As there were only marginal differences between the 2 growth charts with respect to most of the effects of supplementation, all data presented are from the NCHS growth standards to facilitate reference to other publications from the SEAMTIZI study group. Significant differences between the 2 standards are mentioned in the ''Results'' section, however, because recent articles have highlighted differences between the 2 growth standards (21, 22) . Height and weight increments were calculated for a standard period of 6 mo from the change over the actual observation period.
Blood samples were obtained either by venapuncture (INMU, NIN, NRDC) or heel prick (UT/UI) and directly stored in a cool box. Statistical analysis. We checked data for normality using the Kolmogorov-Smirnov test of normality. Effects of iron and zinc supplementation on anthropometrical indicators (HAZ, WAZ, and WHZ scores) were investigated using ANOVA with baseline Z-scores as covariate, controlling for site and gender and using a full factorial analysis. We also investigated the effects of supplementation on increments in weight and height during the 6-mo supplementation period with ANOVA, again controlling for site and gender. This statistical approach is considered the most conservative, because repeated-measures analysis could result in an overestimation of effect size (25, 26) . We checked the regression equations and residual statistics, as the different sites were not homogenous subsets of each other. Main effects were considered significant if P , 0.05 and 2-way interactions if P , 0.10. All 2-way interactions were further explored, except for interactions with site. Effect sizes were calculated from estimated means using the full factorial model. Differences among groups at baseline were tested using Bonferroni post hoc comparison or chi-square statistics for prevalence and using the nonparametric Kruskal Wallis test for compliance. Differences in the prevalence of stunting and wasting at the end of the study were analyzed with binary logistic regression analysis, again controlling for site, gender, and baseline status.
Finally, we investigated the effects of 4 baseline factors [stunting (HAZ , 22.0), anemia, zinc deficiency, and birth weight] that have been reported in the literature to modify the effect of iron or zinc supplementation on anthropometry. To investigate whether these factors significantly contributed to the model, baseline stunting and presence of anemia or zinc deficiency prior to supplementation, and birth weight (coded into 3 categories: low, birth weight #2500 g; normal, birth weight ¼ 2501-3500 g; and high, birth weight .3500 g) were included as independent factors in the model. Baseline biochemistry was available for only approximately one-half of the subjects. One site (NRDC) did not take baseline blood samples and 2 sites (INMU, UT/UI) conducted baseline biochemistry in subgroups only. Furthermore, 1 site (UT/UI) did not measure zinc concentrations. However, the subgroup of subjects with baseline blood samples did not differ from the other subjects in anthropometrical indices. Birth weight was by recall from the mother or from health records. Data on birth weight were available for 1333 infants (46.5%).
Results
In total, 2867 infants were recruited, of whom 2451 (85%) completed the 6 mo of supplementation. Although there were significant differences in several variables among the 4 study sites at recruitment ( Table 1) , there were no differences among the 4 supplementation groups after pooling of the data ( Table 2) .
Overall, there was no significant effect of either iron or zinc supplementation on the increments in height or weight over the 6-mo supplementation period, nor on mean HAZ, WAZ, or WHZ scores (Tables 3 and 4) . However, logistic regression showed that infants receiving zinc were less likely to be stunted than infants not receiving zinc [odds ratio (OR) 0.80; 95% CI 0.64-1.0; P ¼ 0.049; Table 5 ], whereas iron supplementation did not affect stunting. Mean HAZ scores decreased in all groups over the supplementation period (Tables 2 and 3) . Moreover, at the end of the study when the infants were ;11 mo old, male infants had a 30% higher risk for being stunted than female infants (OR 1.42; 95% CI 1.14-1.7; P ¼ 0.002) when using the NCHS growth standards. This gender effect was also evident, but less pronounced, in the WHO growth standards (OR 1.23; 95% CI 0.98-1.55; P ¼ 0.07).
Stunting (HAZ , 22.0) at baseline did not modify the effect of either iron or zinc supplementation. Although only 180 infants were stunted at baseline, a less strict definition of stunting at baseline (HAZ , 21.5, n ¼ 475) did not change these results.
Data on Hb concentration at baseline were available for 1212 infants and showed that 36.6% (n ¼ 443) were anemic (Hb ,105 g/L) at baseline. Anemia at baseline did not affect HAZ, WAZ, or WHZ scores but modified the effect of zinc supplementation on HAZ and WAZ scores (P ¼ 0.005 and P ¼ 0.037 for interaction, respectively). In anemic infants, those receiving zinc for 6 mo had 0.17 higher HAZ scores and 0.14 higher WAZ scores than infants not receiving zinc (P ¼ 0.003 and P ¼ 0.027, respectively; Table 4 ). Although there was no significant interaction between iron and zinc supplementation on HAZ scores in anemic infants (P ¼ 0.18 for interaction), group-by-group analysis showed that infants receiving only zinc benefited most, with an estimated 0.25 higher HAZ score than infants in the placebo group (P ¼ 0.018). Infants receiving the combination of iron and zinc had an estimated increase in HAZ score of 0.19 compared with the placebo group (P ¼ 0.10). In contrast, in infants not anemic at baseline, zinc supplementation did not affect HAZ or WAZ scores. This positive effect of zinc supplementation in infants anemic at baseline on HAZ and WAZ scores was supported by positive effects on increments in height (estimated effect size, 0.33 cm; P ¼ 0.019) and weight (estimated effect size, 0.11 kg; P ¼ 0.034). Interestingly, the WHO growth standards gave almost identical results, with zinc supplementation in anemic infants resulting in 0.18 higher HAZ scores (P , 0.01) and 0.15 higher WAZ scores (P ¼ 0.02). Iron supplementation did not affect anthropometrical indices in anemic or nonanemic infants (Table 4) . Baseline plasma zinc concentrations were measured in 809 infants at only 2 sites. However, mean zinc concentrations differed considerably between the 2 sites, making the definition of zinc deficiency (using a cut-off of serum zinc , 10.7 mmol/L) less useful. Redefining zinc deficiency as plasma zinc concentrations in the lowest quartile at each site showed no significant interaction with either iron or zinc supplementation but revealed a significant effect of initial low zinc concentrations on WHZ scores at the end of the study. Infants in the lowest quartile of zinc concentrations at baseline had an estimated 0.11 lower WHZ score at the end of the study (P ¼ 0.018).
Data on birth weight were available for 1333 infants, 141 (10.6%) of which had a reported low birth weight (,2500 g). As expected, birth weight affected anthropometrical indices at the end of the supplementation period (P , 0.001 for all), with low birth weight infants having lower HAZ scores (mean 21.65 Z-score) than infants born in the normal (21.23 Z-score) and high (20.85 Z-score) birth weight categories, all different from each other (P , 0.001). The effect of birth weight on WHZ scores was much less pronounced, with low birth weight infants having only lower WHZ scores than infants in the high birth weight categories (20.67 as compared with 20.43 z-score; P ¼ 0.03). However, birth weight also modified the effect of iron supplementation on HAZ (P for interaction ¼ 0.005) and WAZ (P for interaction ¼ 0.035) scores. In infants with a high birth weight (.3500 g), iron supplementation had an estimated negative effect of 20.14 HAZ score (P ¼ 0.008), whereas the estimated effect in the other 2 birth weight groups was 10.05 HAZ score (P . 0.1). A similar pattern was seen for the WAZ score, with estimated effect sizes of iron supplementation of 10.13 Z-score (P ¼ 0.14) in low birth weight infants, 10.08 (P ¼ 0.046) in normal birth weight infants, and 20.07 (P . 0.2) in infants with a birth weight .3500 g. 3 Height and weight change were calculated for a standard period of 6 mo from the change over the actual observation period. 4 The prevalence of wasting was ,1%. 
Discussion
The results of this multi-country study show that blanket supplementation neither with iron nor with zinc can prevent the progressive decrease in anthropometrical Z-scores during the first year of life in SE Asia, regardless of the reference growth chart used. All infants were breast-feeding at recruitment and almost all infants (.99%) were still breast-feeding at the end of the study. The prevalence of stunting at the end of the study, when the infants were 11 mo old, was .20%, regardless of iron or zinc supplementation and regardless of whether the NCHS or WHO growth chart was used. Moreover, this study shows that male infants are more likely to become stunted than female infants, with a 19-30% higher risk for stunting, depending on which growth standard is used. This higher risk for stunting in boys is not specific for SE Asia, as Wamani et al. (27) recently reported that in a pooled analysis of 16 African studies, boys had a 16% higher risk of being stunted than did girls. Also, we showed that male infants had a much higher risk to develop iron deficiency during the first year of life than females (12) . Hence, although iron deficiency is prevalent in these infants, correction of only iron and/or zinc deficiency is not enough to prevent stunting. However, this study identified subgroups of infants in which supplementation of iron or zinc can have important effects on growth. The differential effect of zinc supplementation in anemic and nonanemic infants has, to our knowledge, not been reported before. Supplementation with zinc in anemic infants for 6 mo improved linear growth by as much as 0.17 Z-score. However, at the same time, zinc supplementation for infants who were not anemic prior to supplementation did not affect linear growth. One reason for this beneficial effect of zinc in anemic infants could be that low Hb concentrations in young infants also reflect low functional zinc status. Deficiencies of iron and zinc often occur concomitantly (28) , as the same dietary factors (e.g. high phytate content of the diet) lead to a low bioavailability of iron as well as of zinc.
At the same time, iron supplementation did not affect anthropometrical indices in anemic and nonanemic infants. One group of infants that clearly did not benefit from iron supplementation with respect to growth was the group of infants with a birth weight .3500 g. In recent years, several groups have reported negative effects of iron supplementation in infants with adequate iron stores. Idjradinata et al. (9) showed that iron supplementation negatively affected weight gain in iron-replete children and Dewey et al. (8) reported that iron supplementation benefited linear growth in infants anemic prior to supplementation, but negatively influenced linear growth in nonanemic infants. Because birth weight is an important determinant of iron stores in infancy (29), we speculate that the same mechanisms underlying the negative effect of iron supplementation in ironreplete infants play a role in the infants with a birth weight .3500 g. In the present study, infants with a birth weight .3500 had higher Hb concentrations at baseline (113.6 g/L) than the infants with a low birth weight (107.5 g/L; P , 0.01) as well as higher ferritin concentrations (geometric means 43.0 mg/L and 24.9 mg/L, respectively; P , 0.01), suggesting better iron stores in infants born weighing .3500 g. On the contrary, infants with a birth weight ,3500 g are likely to benefit from iron supplementation during infancy, as shown by their tendency toward improved growth after iron supplementation (effect size 0.05 Z-score; P ¼ 0.15).
There is some concern that the cut-off value presently used by WHO to identify anemia in infants (Hb , 110 g/L) is too high, leading to an overestimation of iron deficiency, and a lower cutoff of 105 g/L has been proposed (23) . We have used this lower cut-off for the analysis in the present article, but the WHO cutoff of 110 g/L also identified a subgroup of infants benefiting from zinc supplementation, although the effect size on HAZ was less pronounced (0.11 Z-score; P ¼ 0.028), whether or not this definition of anemia reflects iron status precisely enough.
It is becoming clear that effects of zinc and iron supplementation are more subtle than previously thought. In the present study, zinc supplementation of infants appeared to protect slightly against becoming stunted but with no overall effect on HAZ scores. Importantly, Hb concentrations ,105 g/L clearly identified a subgroup of infants benefiting from zinc supplementation, pointing to a way in which to target interventions. Although not significant, the negative effect of zinc supplementation on linear growth in infants not anemic (20.04 Z-score) prior to supplementation warrants further research. In this study, we used a conservative statistical approach (ANOVA with baseline values as covariate) to estimate effects of supplementation. However, using another common approach, repeatedmeasurement analysis, the negative effect of zinc supplementation in infants not anemic at baseline became significant (P ¼ 0.049), with an estimated negative effect of 20.14 Z-score. In a recent paper by Bhutta et al. (30) , zinc supplementation for infants from 6 mo onwards is recommended as a core intervention for improving child health. As non nocere (do no harm) should be the guiding principle for all health interventions, this negative effect of zinc supplementation on linear growth in infants without anemia and its determinants should be confirmed and explored. For example, it might well be that the dose of zinc used in the current study (10 mg of zinc) is too high for infants.
It is clear from this study that blanket supplementation with iron or zinc will not be beneficial to all recipients and may have adverse effects in some. The fact that differential effects of iron supplementation on growth in iron-deficient and iron-replete infants were recently reported, combined with the similar pattern for zinc supplementation in this study, indicates that the effect of micronutrient supplementation on growth needs to be reexamined, taking baseline characteristics such as anemia and gender into account. Also, although there was no significant interaction between iron and zinc with respect to growth in this study, Lind et al. (31) reported that a beneficial effect of zinc supplementation in Indonesian infants disappeared with the addition of iron. Other studies have shown that iron supplementation in children in malaria endemic areas led to an increase in morbidity and mortality (32) . Before recommendations on interventions to improve iron and zinc status of infants at risk for deficiency can be made, many questions need to be answered. One very important question is whether these negative effects are still present to the same extent when a fortification approach is used rather than supplementation.
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